Gainers

• Healthcare Triangle (NASDAQ:HCTI) shares increased by 66.3% to $9.66 during Thursday's pre-market session. The market value of their outstanding shares is at $4.3 million.
• Curanex Pharmaceuticals (NASDAQ:CURX) stock moved upwards by 52.77% to $0.48. The company's market cap stands at $8.9 million.
• Kairos Pharma (AMEX:KAPA) stock moved upwards by 23.57% to $0.78. The market value of their outstanding shares is at $13.0 million.
• Profusa (NASDAQ:PFSA) stock rose 19.84% to $1.51. The market value of their outstanding shares is at $1.7 million.
• Butterfly Network (NYSE:BFLY) shares moved upwards by 14.51% to $3.55. The company's market cap stands at $783.0 million. As per the news, the Q4 earnings report came out today.
• Century Therapeutics (NASDAQ:IPSC) stock rose 12.38% to $2.45. The market value of their outstanding shares is at $190.3 million.

Losers

• PROCEPT BioRobotics (NASDAQ:PRCT) shares decreased by 25.7% to $20.69 during Thursday's pre-market session. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out yesterday.
• GoodRx Holdings (NASDAQ:GDRX) stock declined by 14.7% to $2.09. The market value of their outstanding shares is at $880.3 million. As per the news, the Q4 earnings report came out yesterday.
• Vir Biotechnology (NASDAQ:VIR) shares decreased by 11.31% to $8.87. The company's market cap stands at $1.3 billion. As per the news, the Q4 earnings report came out 3 days ago.
• Teleflex (NYSE:TFX) shares decreased by 9.74% to $101.0. The market value of their outstanding shares is at $4.9 billion. As per the press release, Q4 earnings came out today.
• Perrigo (NYSE:PRGO) shares declined by 9.44% to $13.05. The company's market cap stands at $1.9 billion. As per the press release, Q4 earnings came out today.
• Matinas BioPharma Hldgs (AMEX:MTNB) stock declined by 8.73% to $0.55. The company's market cap stands at $3.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

• No comments yet. Be the first to comment!